Document is current
Any future updates will be listed below
-
Authors
Builes-Montaño, Carlos E. https://orcid.org/0000-0002-2418-6159
Suarez-Rodriguez, Andres F. https://orcid.org/0009-0004-6502-0819
Alzate-Vinasco, Maria A. https://orcid.org/0009-0006-6247-6049
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 23 March 2026
Accepted: 21 May 2026
First Online: 7 June 2026
Declarations
Conflict of Interest: The authors declare the following conflicts of interest: Carlos E. Builes-Montaño has received consulting and speaking fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Janssen, Chiesi, Abbott, and Boehringer Ingelheim, and is a shareholder of Festina Lente. Andres F. Suarez-Rodriguez and Maria A. Alzate-Vinasco are employees of Novo Nordisk, the sponsor of the research project from which this work was derived. These disclosures are not necessarily related to the submitted work.
Ethical Approval: This study was based exclusively on aggregated, arm-level data extracted from previously published clinical trials. No individual participant data were used. Therefore, institutional review board approval and informed consent were not required for the present secondary analysis. According to the information reported in the original trial publications, the included studies received approval from the corresponding ethics committees or institutional review boards, were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, and obtained written informed consent from all participants.
